🧬 Aging Wiki

lipoprotein-metabolism

Properties1
aliaseslipoprotein metabolism, lipoprotein flux, plasma lipoprotein cycle, lipoprotein transport, cholesterol transport

17 min read

Lipoprotein metabolism pathway

Lipoprotein metabolism describes the coordinated flux of lipid-carrying particles through plasma — from dietary fat absorption in the gut, through hepatic synthesis and secretion, to peripheral delivery and return of cholesterol to the liver. This pathway is the mechanistic underpinning of atherosclerosis, the dominant cause of cardiovascular mortality in aging populations, and the target of the most-validated lipid-lowering pharmacology available. Dysfunction accumulates silently over decades; cumulative atherogenic-particle exposure is the proximate driver of cardiovascular events, making this pathway a central aging-risk integrator 1.

Reactome: R-HSA-174824 “Plasma lipoprotein assembly, remodeling, and clearance”
KEGG: hsa04979 “Cholesterol metabolism – Homo sapiens”

Pathway overview

Five mechanistically distinct but coupled sub-pathways carry lipid from diet and hepatic synthesis to peripheral tissues and back:

Sub-pathwayDirectionKey particlesKey proteins
Exogenous (dietary)Gut → lymph → systemicChylomicrons, remnantsapob-48, mtp, npc1l1, lpl, LRP1
Endogenous (hepatic)Liver → periphery → liverVLDL → IDL → LDLapob-100, mtp, lpl, ldlr, pcsk9
Reverse cholesterol transportPeriphery → liverHDL (nascent → mature)abca1, lcat, cetp, SR-B1, apoa1
Lp(a)Liver → plasma (rogue)Lp(a)lpa, apob-100
Free fatty acid fluxAdipose ↔ liver/muscleAlbumin-FFAHSL, LPL, ATGL

1. Exogenous (dietary) pathway

Dietary fat absorption begins in the enterocyte. Cholesterol crosses the apical brush border via NPC1L1 — the molecular target of ezetimibe — while long-chain fatty acids and monoglycerides are taken up by CD36 and FATP4. Inside the enterocyte ER:

  • DGAT1/2 re-esterifies fatty acids → triglyceride (TG)
  • ACAT2 (SOAT2) esterifies free cholesterol → cholesterol ester (CE)

Chylomicron assembly is rate-limited by MTP (microsomal triglyceride transfer protein), which loads TG and CE onto nascent ApoB-48 — the intestine-specific truncated isoform generated by APOBEC1 mRNA editing of the APOB transcript at codon 2153 (glutamine → stop). MTP inhibition is the mechanism of lomitapide (approved for homozygous familial-hypercholesterolemia). Assembled chylomicrons (diameter 75–1200 nm, TG-rich core) exit the enterocyte into lymphatic lacteals, travel through the thoracic duct, and enter systemic circulation via the subclavian vein — bypassing first-pass hepatic metabolism.

In the capillary beds of muscle and adipose, LPL (lipoprotein lipase, anchored to capillary endothelium via GPI-HBP1) hydrolyzes chylomicron TG → free fatty acids + glycerol. This delivers dietary fat to peripheral tissues and shrinks the particle to a chylomicron remnant. Remnants (still carrying ApoB-48 and ApoE) are cleared from circulation by the liver, primarily via LRP1 (LDL receptor-related protein 1) using ApoE as the ligand, with ldlr playing a secondary role 2.

Postprandial hypertriglyceridemia — the period of elevated circulating chylomicrons and remnants after a meal — is prolonged in older individuals, a consequence of reduced LPL activity and slower remnant-receptor clearance. needs-replication (age-specific mechanistic data from well-powered human studies are limited)

2. Endogenous pathway (hepatic VLDL → LDL)

The liver continuously produces and secretes VLDL (very-low-density lipoprotein) as the vehicle for distributing hepatic-derived TG and cholesterol to peripheral tissues. Assembly parallels chylomicron formation:

  • MTP loads TG/CE onto ApoB-100 (full-length, 4,563-residue protein; see apob) in the ER
  • Nascent VLDL (40–80 nm) is secreted into the space of Disse and then portal sinusoids

In plasma, the VLDL → IDL → LDL cascade proceeds by sequential TG hydrolysis:

  1. LPL (same endothelial enzyme as above, regulated by apoC-II activator and apoC-III inhibitor) hydrolyzes VLDL TG → IDL (intermediate-density lipoprotein)
  2. Hepatic lipase (LIPC) further hydrolyzes IDL TG + phospholipids → LDL (low-density lipoprotein)

LDL is the terminal, cholesterol-enriched (CE ~40% by mass) product of hepatic VLDL secretion. It is the primary cholesterol-delivery vehicle to all nucleated cells. LDL clearance depends almost entirely on cell-surface ldlr:

  • ~70% of LDL cleared by hepatic LDLR via endocytosis (clathrin-coated pits)
  • LDLR binds ApoB-100 (the recognition ligand on LDL) with high affinity
  • After endocytosis, LDL is degraded in lysosomes; LDLR is recycled back to the surface (~150 cycles per receptor lifetime)

PCSK9 modulates this flux by binding LDLR in the endosome and routing it to lysosomal degradation rather than recycling, thereby reducing surface LDLR density and elevating plasma LDL. PCSK9 inhibition (via monoclonal antibodies evolocumab, alirocumab) is the most potent available LDL-lowering strategy 3 4.

SREBP-2 is the master transcriptional regulator. When hepatic cholesterol falls (e.g., after statin therapy), srebp-2 is proteolytically activated and drives transcription of both LDLR and HMGCR — simultaneously increasing LDL uptake and endogenous cholesterol synthesis. This SREBP-2 feedback loop is the mechanistic basis for why statins upregulate LDLR: statin-mediated HMGCR inhibition → ↓ intracellular cholesterol → ↑ SREBP-2 cleavage → ↑ LDLR transcription → ↑ LDL clearance.

Non-LDLR LDL clearance routes (~30% of total):

  • Scavenger receptor A (SR-A) and CD36 on macrophages — uptake of oxidized LDL (oxLDL) → foam cell formation → atherogenic 5
  • Hepatic SR-B1 (minor route for LDL; major route for HDL-CE; see below)

3. Reverse cholesterol transport (HDL pathway)

HDL mediates the centripetal movement of excess cholesterol from peripheral tissues (including arterial macrophages) back to the liver — the pathway termed reverse cholesterol transport (RCT). This is the primary atheroprotective function of HDL. However, the clinical story is complicated: plasma HDL-C concentration does not predict cardiovascular risk causally by Mendelian randomization, while RCT functional capacity and HDL particle quality remain plausible mediators 6.

RCT steps:

  1. ApoA-I (primary HDL apolipoprotein) is secreted by liver and intestine as a lipid-poor protein
  2. ABCA1 (ATP-binding cassette transporter A1; the Tangier disease gene when mutated) effluxes free cholesterol and phospholipids from cell membranes onto ApoA-I → nascent (discoidal) HDL
  3. LCAT (lecithin-cholesterol acyltransferase) esterifies free cholesterol on HDL surface → CE moves to core → spherical, mature HDL (HDL3 → HDL2)
  4. CETP (cholesteryl ester transfer protein) exchanges HDL-CE for VLDL/LDL-TG — transferring CE from HDL back onto atherogenic particles. This “atherogenic redistribution” reduces HDL-CE and enriches LDL with CE from peripheral tissues.
  5. SR-B1 (scavenger receptor class B type 1) mediates selective CE uptake from mature HDL into hepatocytes (without whole-particle uptake), enabling biliary excretion — the completion of RCT.

The CETP inhibitor experience. Four CETP inhibitors have been through large Phase 3 trials. Three clearly failed: torcetrapib (raised BP via off-target aldosterone/endothelin effect, increased CV deaths), dalcetrapib (stopped for futility, no safety signal), and evacetrapib (stopped for futility). Anacetrapib (REVEAL trial, n=30,449, median 4.1 years) showed a statistically significant reduction in the primary composite (coronary death/MI/revascularization: rate ratio 0.91, p<0.004), but Merck elected not to pursue FDA approval, largely due to the drug’s extreme lipophilicity and accumulation in adipose tissue. Importantly, anacetrapib’s benefit appears attributable primarily to its LDL-C and non-HDL-C lowering (−17% and −18% respectively) rather than its HDL-C raising. The collective experience supports the view that HDL-C is a biomarker, not a causal mediator of CV protection — the atheroprotective signal lies in RCT function and HDL particle composition, and any CV benefit from CETP inhibition tracks non-HDL-C/LDL-C reduction, not HDL-C concentration 6. Obicetrapib (next-generation CETP inhibitor, more potent and selective) showed 48.6% LDL-C reduction in the Phase 3 TANDEM trial (n=407) when combined with ezetimibe as a fixed-dose combination vs placebo, repositioning CETP inhibition as an LDL-lowering rather than HDL-raising strategy 7. needs-replication — CV outcomes data for obicetrapib are pending.

4. Lp(a) — the rogue particle

Lp(a) (lipoprotein(a)) is a distinct lipoprotein class that consists of an LDL-like particle (ApoB-100 core, CE-enriched) covalently linked via a disulfide bond to apo(a) — a large glycoprotein encoded by the LPA gene on chromosome 6q25-26.

Apo(a) structure: structurally homologous to plasminogen, apo(a) contains multiple kringle IV repeats (subtypes 1–10) plus a single kringle V and a serine protease-like domain (catalytically inactive). The number of kringle IV type-2 (KIV-2) repeats is genetically variable — the LPA gene locus has a copy-number polymorphism causing extreme variation in apo(a) isoform size. Smaller apo(a) isoforms (fewer KIV-2 repeats) → higher plasma Lp(a). The KIV-2 CNV alone explains 61–69% of the variance in Lp(a) levels in European populations, but only 19–44% in African populations; additional sequence variants in the LPA promoter and gene body explain further variance 8.

Heritability: ~70–90% of plasma Lp(a) is genetically determined. Diet, exercise, and standard lipid-lowering therapies have minimal effect on Lp(a) levels. Statins may paradoxically raise Lp(a) slightly.

Atherogenicity: Lp(a) is both atherogenic and prothrombotic — apo(a)‘s structural homology to plasminogen means it can compete with plasminogen for fibrin binding, impairing fibrinolysis. Mendelian randomization studies confirm that genetically elevated Lp(a) is causally associated with coronary heart disease (CHD), aortic stenosis, and ischemic stroke 9.

Emerging Lp(a)-lowering therapies:

  • Pelacarsen (TQJ230) — hepatocyte-targeted antisense oligonucleotide against LPA mRNA; Phase 3 Lp(a)HORIZON trial (cardiovascular outcomes; ongoing as of 2026)
  • Olpasiran (AMG890) — GalNAc-conjugated siRNA against LPA; Phase 3 OCEAN(a)-Outcomes (ongoing as of 2026)
  • Muvalaplin — small-molecule oral inhibitor of apo(a)–ApoB interaction, blocking Lp(a) particle assembly; Phase 2 (positive Lp(a)-lowering data; no CV outcomes trial yet)

Clinical-trial status for this class is rapidly evolving. long-term-unknown — CV outcomes data pending.

5. Free fatty acid (FFA) flux and metabolic-syndrome dyslipidemia

Adipose tissue lipolysis releases non-esterified fatty acids (NEFAs / FFAs) into plasma, where they circulate albumin-bound and are taken up by liver and muscle for β-oxidation. This flux is tightly regulated:

  • Insulin suppresses adipose lipolysis postprandially (via phosphodiesterase-3B activation → ↓ cAMP → ↓ PKA → ↓ HSL/ATGL activity)
  • Fasting / catecholamines / glucagon activate lipolysis

In insulin resistance (metabolic syndrome, type 2 diabetes), this regulation breaks down:

  • Adipose lipolysis escapes insulin suppression → ↑ FFA delivery to liver
  • Hepatic FFA excess → ↑ TG synthesis → ↑ VLDL assembly and secretion
  • ↑ VLDL TG floods plasma → LPL-mediated remodeling produces small, dense LDL (sdLDL) and remnant lipoproteins — both more atherogenic than large, buoyant LDL
  • Simultaneously, ↑ CETP activity transfers CE from HDL to VLDL → ↓ HDL-C + ↑ HDL-TG → HDL particles become TG-enriched and are cleared faster → net HDL-C falls

This metabolic-syndrome dyslipidemia triad — high TG, low HDL-C, elevated sdLDL — is mechanistically downstream of adipose lipolysis dysregulation, not primary hypercholesterolemia 5.

Palmitate (palmitic-acid; C16:0), the predominant saturated FFA released by adipose lipolysis, drives hepatic VLDL secretion and also directly promotes de-novo lipogenesis via SREBP-1c. Dietary PUFA replacement of palmitate shifts the VLDL and LDL flux toward less atherogenic particle profiles (the mechanistic basis of mediterranean-diet benefit).

Aging relevance

LDL-clearance capacity declines with age — but the mechanism is SREBP-2 hyperactivation with PCSK9 dominance, not reduced SREBP-2 processing

⚠️ Direction corrected 2026-05-21 — the prior shorthand “reduced SREBP-2 processing efficiency” was a field convention that did not survive direct empirical scrutiny. The best-supported current model:

  1. SREBP-2 nuclear activity is elevated per hepatocyte in aged liver — Yang et al. 2024 single-nucleus transcriptomic atlas of cynomolgus monkey liver across three hepatocyte zonations identifies hyperactivated SREBP signaling as a defining hallmark of the aged hepatocyte; forced SREBP2 activation in human primary hepatocytes is sufficient to recapitulate aging phenotypes (impaired detoxification, accelerated cellular senescence) 10. This is consistent with — and the first direct empirical anchor for — the longstanding mechanistic prediction that age-associated mTORC1 hyperactivation maintains SREBP-2 above set-point (see mtor → lipin-1 → srebp-2 in Peterson 2011).
  2. PCSK9 feedback dominance produces the observed surface LDLR decline — SREBP-2 transcribes both LDLR and PCSK9 (Dubuc 2004; Jeong 2008 — see srebp-2 § PCSK9 feedback paradox). When SREBP-2 is hyperactivated, both arms go up, but PCSK9 post-translationally degrades the LDLR protein faster than transcription can replace it. Plasma PCSK9 protein has been reported to rise with age (Cui 2010; Lakoski 2009 — pre-2015 anchors, no modern healthy-cohort replication). The net phenotype is reduced hepatic surface LDLR and slower plasma LDL clearance.
  3. Bulk-vs-single-cell methodological caveat. Bulk RNA-seq of human liver (GTEx v10, this wiki’s 2026-05-21 query) shows essentially flat hepatic SREBF2, LDLR, and PCSK9 transcript trends with age (|ρ| ≤ 0.08, n=262). Yang 2024’s snRNA-seq direction disagrees with the bulk data — the canonical resolution is the cell-composition confound: aged liver has reduced hepatocyte fraction (immune/stellate infiltration, fibrosis), diluting per-hepatocyte increases out of bulk tissue measurements. Single-cell/single-nucleus data is the appropriate instrument; bulk is misleading.
  4. Largest extrahepatic GTEx aging signal in this pathway: visceral adipose LDLR drops ~70% (median TPM 109 → 34, ρ=−0.22, n=587) from age 20-29 to 50-59. Adipose LDLR mediates lipid delivery for steroidogenesis and energy storage; whether the drop reflects per-adipocyte decline or cell-composition shift (aged VAT becoming more inflammatory/stromal) is uncharacterized. Surfaces a previously-unexamined aging signature on ldlr. needs-replication

The clinical consequence is unchanged: plasma LDL/ApoB clearance declines with age and cumulative LDL exposure rises (§ Cumulative LDL-exposure framework below). The mechanistic correction is in how it happens — implications include that PCSK9 inhibition is more mechanism-specific against aging-driven LDL elevation than statins alone, because statins push SREBP-2 harder (more LDLR transcription and more PCSK9) while PCSK9i directly relieves the dominant brake.

Postprandial lipemia is more sustained in older individuals

LPL activity and chylomicron-remnant clearance capacity decline with age, resulting in prolonged postprandial hypertriglyceridemia — a state associated with increased remnant lipoprotein exposure, which is independently atherogenic even when fasting LDL-C is normal 5. needs-replication — mechanistic studies in well-characterized elderly cohorts are limited.

Cumulative LDL-exposure framework

Genetic studies of PCSK9 loss-of-function carriers demonstrate that lifelong lower LDL-C exposure translates to markedly reduced CHD risk out of proportion to what short-term statin trials would predict. The analysis by Wang et al. (2022) formalizes this: longer duration of cholesterol-lowering produces compounding CV-event reduction beyond what event-rate modeling from individual trial follow-up predicts 11. This supports the inference that LDL-years (integral of LDL-C × time) is the causal metric — not current LDL-C level — and implies that early-life lipoprotein control disproportionately reduces lifetime CVD risk. This is the core mechanistic rationale for starting aggressive LDL-lowering earlier.

Connection to hallmarks

  • Altered intercellular communication — atherogenic lipoprotein particles (oxLDL, remnants) act as intercellular lipid signals that activate endothelial inflammation, NLRP3 inflammasome in arterial macrophages, and promote foam-cell senescence
  • Chronic inflammation — Lp(a) activates oxidative stress and pro-inflammatory gene expression; remnant lipoprotein remnants drive macrophage activation; foam-cell senescence amplifies the nlrp3-inflammasome SASP
  • Lipoprotein-driven arterial inflammation is a major upstream driver of atherosclerosis, which feeds back to systemic inflammatory burden as plaque rupture and plaque-associated SASP secretion escalates with age

Therapeutic targeting (pathway-level summary)

Detailed pharmacology on entity pages. Summary of targets by mechanism of action:

Agent classTargetPrimary effectEntry
Statinshmgcr (HMGCR inhibition)↓ cholesterol synthesis → ↑ SREBP-2 → ↑ LDLR → ↑ LDL clearancestatins
Ezetimibenpc1l1 (NPC1L1 internalization-block)↓ intestinal cholesterol absorption → ↑ hepatic LDLR (SREBP-2 axis); IMPROVE-IT 2015 first non-statin LDL-lowering CV-outcomes RCTezetimibe
PCSK9 inhibitors (mAb / siRNA)pcsk9↑ LDLR surface density → ↑ LDL clearancepcsk9
Bempedoic acidACLY (ATP-citrate lyase)↓ acetyl-CoA → ↓ cholesterol synthesis → ↑ SREBP-2 → ↑ LDLR; liver-specific ACSVL1 bioactivation → no SAMS; CLEAR Outcomes 2023 HR 0.87bempedoic-acid
Lomitapidemtp↓ chylomicron + VLDL assembly → ↓ ApoB-particle productionmtp
EvinacumabANGPTL3↓ ANGPTL3 → ↑ LPL + EL activity → LDLR-independent LDL clearanceangptl3 (stub)
CETP inhibitors (obicetrapib)cetp↑ HDL-C; obicetrapib also lowers LDL-C 48.6% in combination (n=407, TANDEM Phase 3) 7cetp
Lp(a)-targeted (pelacarsen, olpasiran)lpa↓ apo(a) production → ↓ Lp(a)lpa

Druggability note (aging context): druggability-tier 1 is assigned because multiple FDA-approved agents (statins, ezetimibe, PCSK9 inhibitors) directly engage this pathway and are validated for aging-relevant CV-risk reduction. This is the most therapeutically tractable metabolic pathway in the wiki. The aging-context tier matches the maximum-druggability tier here (unlike mtor vs rapamycin for aging vs transplant).

Cross-pathway connections

  • srebp-2 — transcriptional master switch integrating intracellular cholesterol to LDLR and HMGCR expression; see mtor (mTOR drives SREBP-1c for lipogenesis, a related but distinct arm)
  • hmgcr — rate-limiting enzyme in mevalonate pathway; statin target
  • insulin-igf1 — insulin suppresses hepatic ApoB secretion postprandially; insulin resistance deregulates VLDL output
  • ampk — activated by energy stress; inhibits fatty acid synthesis and promotes FAO; also inhibits HMGCR (phosphorylation); counteracts obesity-driven dyslipidemia
  • nlrp3-inflammasome — activated by cholesterol crystals in atherosclerotic plaques; links lipoprotein-derived lipid overload to sterile inflammaging
  • cellular-senescence — foam cells in atherosclerotic plaques are senescent; their SASP amplifies arterial inflammation and plaque progression

Limitations and gaps

  • LDLR aging-decline mechanism: age-related reduction in hepatic LDLR activity is documented in animal models; human mechanistic data are thin. needs-human-replication
  • Postprandial lipemia in aging: epidemiological associations exist; causal mechanisms and intervention data in older adults are limited. needs-replication
  • Obicetrapib CV-outcomes data: Phase 3 TANDEM establishes LDL-C lowering; REDUCE-IT-style CV endpoint trial pending. long-term-unknown
  • Lp(a) outcome trials: Lp(a)HORIZON (pelacarsen) and OCEAN(a)-Outcomes (olpasiran) are the first large RCTs testing whether Lp(a) lowering reduces CV events. Both ongoing as of 2026-05; CV outcomes data pending. long-term-unknown
  • RCT function as a causal mediator: HDL-C is not causal by MR; whether functional RCT capacity per se is causal remains an open question (no suitable instrument for MR). no-mechanism
  • FFA flux in aging: adipose lipolysis dysregulation in aging (versus metabolic syndrome) is undercharacterized as a distinct pathway. needs-replication

Footnotes

Footnotes

  1. doi:10.1126/science.3513311 · Brown MS, Goldstein JL · Science 1986 · review · “A receptor-mediated pathway for cholesterol homeostasis” · Nobel Lecture formalization of the LDLR endocytic pathway; 5,659 citations; closed access (not_oa per a local paper archive) ↩

  2. doi:10.1016/j.ecl.2022.02.008 · Feingold KR · Endocrinol Metab Clin North Am 2022 · review · “Lipid and lipoprotein metabolism” — canonical reference for sub-pathway mechanics; PMID 35963623 · not_oa (closed access per a local paper archive; sub-pathway mechanics attributed to this source not independently re-verified against full text) ↩

  3. doi:10.1056/NEJMoa1615664 · Sabatine MS, Giugliano RP et al. · NEJM 2017;376:1713–1722 · randomized · FOURIER trial; evolocumab vs placebo on background statin therapy; n=27,564 (13,784 evolocumab / 13,780 placebo); median follow-up 2.2 years; least-squares mean LDL-C reduction 59% at 48 weeks (95% CI 58–60, p<0.001); primary endpoint (CV death/MI/stroke/UA/revascularization): HR 0.85, 95% CI 0.79–0.92, p<0.001; key secondary endpoint (CV death/MI/stroke): HR 0.80, 95% CI 0.73–0.88, p<0.001 · local PDF verified at archive ↩

  4. doi:10.1056/NEJMoa1801174 · Schwartz GG, Steg PG et al. · NEJM 2018;379:2097–2107 · randomized · ODYSSEY OUTCOMES trial; alirocumab vs placebo post-ACS; n=18,924; primary endpoint (CHD death/nonfatal MI/fatal-nonfatal ischemic stroke/unstable angina): HR 0.85, 95% CI 0.78–0.93, p<0.001; all-cause mortality also reduced (HR 0.85, 95% CI 0.73–0.98); all-cause mortality reduction more pronounced in pre-specified high-Lp(a) subgroup · local PDF available at archive ↩

  5. doi:10.1093/eurheartj/ehab551 · Ginsberg HN, Packard CJ, Chapman MJ et al. · European Heart Journal 2021;42:4791–4806 · consensus statement · European Atherosclerosis Society; triglyceride-rich lipoproteins, remnants, atherogenesis, and emerging therapies; remnant particles contain up to 4× more cholesterol per particle than LDL (up to 10,000 vs 2,000–2,700 cholesterol molecules); per-particle remnants are more potent foam-cell inducers than LDL · local PDF available at archive ↩ ↩2 ↩3

  6. doi:10.1161/CIRCRESAHA.117.311978 · Tall AR, Rader DJ · Circulation Research 2018;122:106–112 · review · “Trials and Tribulations of CETP Inhibitors”; synthesis of torcetrapib, dalcetrapib, evacetrapib, anacetrapib Phase 3 trial results; REVEAL showed rate ratio 0.91, p<0.004 for anacetrapib (n=30,449); articulates that CV benefit tracks non-HDL-C/LDL-C reduction, not HDL-C; Merck did not pursue FDA approval · local PDF available at archive ↩ ↩2

  7. doi:10.1016/s0140-6736(25)00721-4 · Sarraju A et al. · The Lancet 2025 · randomized · TANDEM trial; obicetrapib + ezetimibe fixed-dose combination vs placebo; Phase 3; n=407 · obicetrapib combo reduced LDL-C 48.6% vs placebo; adverse event rates similar across groups; CV outcomes data pending long-term-unknown · not_oa (closed access per a local paper archive; n and LDL-C % confirmed via PMID 40347969 abstract) ↩ ↩2

  8. doi:10.1194/jlr.R067314 · Schmidt K, Noureen A, Kronenberg F, Utermann G · Journal of Lipid Research 2016;57:1339–1359 · review · “Structure, function, and genetics of lipoprotein (a)”; KIV-2 CNV explains 61–69% of Lp(a) variance in Europeans, 19–44% in Africans; heritability (h²) 70–≥90% in all populations studied; LPA locus is the major controlling locus; plasminogen structural homology and putative antifibrinolytic mechanism · local PDF available at archive ↩

  9. doi:10.1001/jamacardio.2018.1470 · Burgess S, Ference BA, Danesh J et al. · JAMA Cardiology 2018;3:619–627 · Mendelian randomization analysis · n=48,333 (CHD Exome+ Consortium + CARDIOGRAMplusC4D replication) · LPA variants as instruments; each 10-mg/dL lower genetically predicted Lp(a) associated with 5.8% lower CHD risk (OR 0.942, 95% CI 0.933–0.951, p=3×10⁻³⁷); ~101.5 mg/dL Lp(a) lowering needed to achieve same CHD risk reduction as 38.67 mg/dL LDL-C lowering · local PDF available at archive ↩

  10. yang-2023-primate-liver-aging-snrna-srebp2 · doi:10.1093/procel/pwad039 · PMID 37378670 · PMC10833472 · Yang S, Liu C,… Liu GH (Aging Biomarker Consortium) · Protein & Cell 2024;15(2):98-120 · in-vivo (cynomolgus monkey single-nucleus liver atlas, multi-age cohort) + in-vitro (human primary hepatocyte forced SREBP2 activation) · hyperactivated SREBP signaling is a hallmark of the aged primate liver across all three hepatocyte zonations; forced SREBP2 activation in human primary hepatocytes is sufficient to recapitulate aging phenotypes (impaired detoxification + accelerated cellular senescence) · Gold OA via OUP/PMC · ⚠️ abstract-verified 2026-05-21; full PDF read pending — study page is verified: false ↩

  11. doi:10.1161/CIRCOUTCOMES.121.008552 · Wang N et al. · Circulation: Cardiovascular Quality and Outcomes 2022 · systematic review and meta-analysis · compounding benefits of cholesterol-lowering therapy; establishes LDL-years framework for duration-dependent CV-event reduction; not_oa (closed access per a local paper archive) ↩

Graph View

Backlinks